FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Cancer Treatment
Relevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
Article : Promising drug for cancer treatment begins clinical trials
Relevance: Medium-Low
Quality of Writing: Medium
Research Timeline: Animal Studies
Most relevant for: People with solid tumors.
Researchers at City of Hope are testing a new type of cancer treatment drug. When tested in animals and cells taken from human cancers, this new drug prevented the growth of many types of cancer. Initial clinical trials in people have just started. (Posted 9/7/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Personalized vaccines may help pancreatic cancer treatment
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with pancreatic cancer who have tumors that can be removed by surgery
Pancreatic cancer is usually diagnosed at a late stage when patients have few treatment options. Early study results showed that a pancreatic cancer vaccine delayed the return of cancer for nearly half of the participants. (Posted 8/29/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : New treatment option for advanced or recurrent endometrial cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced or recurrent endometrial cancer
If you have advanced or recurrent endometrial cancer, there is a new treatment called Jemperli (dostarlimab) that could be an option for you. This study looked at how well Jemperli worked compared to standard treatment. Based on these results, the Food and Drug Administration (FDA) approved the combination of Jemperli and chemotherapy for certain types of advanced endometrial cancer. (Posted 8/4/23)
Este artículo está disponible en español.
Read More
Study : Breast cancer disparities among the LGBTQ+ community
Most relevant for: People belonging to the LGBTQ+ community
This study looked at differences in breast cancer treatment outcomes among people from the LGBTQ+ community. (Posted 6/28/23)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Breast cancer outcomes improved with CDK4/6 inhibitor treatment
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: People with HR-positive HER2-negative advanced breast cancer
A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : New oral drug treatment for some advanced breast cancer
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with HR-positive, HER2-negative advanced breast cancer
The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Study : Promising early results for treating metastatic prostate cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)
The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)
Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage.
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Study : Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people
Relevance: High
Strength of Science: High
Most relevant for: People with early-stage breast cancer who are post-menopausal
A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Trodelvy benefits people with advanced hormone-positive metastatic breast cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with ER/PR-positive, HER2-negative metastatic breast cancer
The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)
Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.
Este artículo está disponible en español.
Read More
Update : Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations
Most relevant for: People with a BRCA1 or PALB2 mutation undergoing prophylactic bilateral mastectomy
A new vaccine was first tested on people diagnosed with triple-negative breast cancer. The vaccine is now being tested to prevent breast cancer among people with an inherited mutation in BRCA1 or PALB2 who are at high risk and who are planning to have a risk-reducing mastectomy. (Posted 1/9/23) Este artículo está disponible en español.
Read More